Clinical trials: Pioglitazone, completed
Inflammation
Effect of Pioglitazone on Oxidative Load, Inflammatory End-Points and Vascular Reactivity in Obese Non-Diabetic Patients: A Dose Ranging Study
Pioglitazone decreases oxidative load, inflammatory end points and improves vascular reactivity in obese patients in a dose dependent manner and that this effect is independent of its glucose lowering effects.
- Trial name
- NCT01161394
- Testing
- Pioglitazone 15mg, pioglitazone 30mg
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- University at Buffalo
Bladder Cancer
Risk of Bladder Cancer in Type 2 Diabetes Patients With Pioglitazone Therapy "PROBE"
Pioglitazone, an agonist of the peroxisome-proliferator-activated receptor (PPAR), is a relatively new oral anti-hyperglycemic drug.
- Trial name
- PROBE-PIO (NCT01935466)
- Testing
- Pioglitazone
- Where
- India
- Volunteers
- 6,107 people
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
End-stage Renal Disease
Peroxisome Proliferator-Activated Receptor-Gamma Activation in Peritoneal Dialysis Patients
To study whether peroxisome proliferator-activated receptor-gamma activation in peritoneal dialysis patients will reduce inflammation, atherosclerosis, calcification and improve survival of peritoneal dialysis patients
- Trial name
- PPAR (NCT00745225)
- Testing
- Pioglitazone
- Where
- Hong Kong
- Volunteers
- 160 people
- Sponsor
- The University of Hong Kong
Systemic Lupus Erythematosus
Role of PPAR-y Agonists in Immunomodulation and Vascular Prevention in SLE (PPAR-SLE)
Background: Lupus causes a person s immune system to attack the body. It can cause blood vessel problems, heart attack, or stroke. Researchers want to see if the drug pioglitazone may help.
- Trial name
- NCT02338999
- Testing
- PET/CT, Pioglitazone
- Where
- United States
- Volunteers
- 88 people
- Sponsor
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
PCOS
Effects of Combined Resveratrol and Myo-inositol on Altered Metabolic, Endocrine Parameters and Perceived Stress in Patients With Polycystic Ovarian Syndrome
The investigators aim is to conduct a double blind randomized clinical trial, to study the effects of combined Resveratrol and Myo-Inositol on altered metabolic, endocrine parameters and perceived stress response in patients with…
- Trial name
- NCT04867252
- Testing
- Resveratrol (1000mg twice a day), Myoinositol 1000mg (Twice a day), Metformin (500 mg Twice a day), Pioglitazone (15 mg Twice a day)
- Where
- Pakistan
- Volunteers
- 88 people
- Sponsor
- Khyber Medical University Peshawar
Type 2 Diabetes Mellitus
Study of Rivoglitazone in Type 2 Diabetes Mellitus
This is a 26-week study in subjects with type 2 diabetes currently sub-optimally controlled by diet and exercise or with non-thiazolidinedione antihyperglycemic monotherapy.
- Trial name
- NCT00484198
- Testing
- Pioglitazone, Rivoglitazone
- Where
- 183 sites in United States, Argentina and 16 more
- Volunteers
- 1,912 people
- Sponsor
- Daiichi Sankyo
Pioglitazone
Pioglitazone Versus Metformin as First Treatment in Infertile Women With Polycystic Ovary Syndrome
Participants with PCOS will be divided into two groups then each group will randomly recieve one of the following treatment 1. metformin will be adminstered in adose of 500 mg 3 times daily for 3 months to group B. 2.
- Trial name
- NCT03566225
- Testing
- Pioglitazone, Metformin, Clomiphene Citrate
- Where
- Egypt
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Ain Shams University
Peripheral Arterial Disease
Study to Evaluate the Effect of Simvastatin, Losartan and Pioglitazone on Patients With Peripheral Arterial Disease.
Part A. The purpose of this study is to assess the effects of 6 weeks of treatment with, simvastatin, losartan or pioglitazone compared to placebo on the RNA expression profile of lower extremity peripheral arterial…
- Trial name
- LEAP (NCT00720577)
- Testing
- Simvastatin, Losartan, Pioglitazone
- Volunteers
- 164 people
- Sponsor
- Medtronic Endovascular
Chronic Myelogenous Leukemia, BCR-ABL Positive, CML, Chronic Phase
Value of Using Pioglitazone in Chronic Myeloid Leukemia Treatment
Assessment of patients response and expression levels of CITED2 and HIF2a genes on adding pioglitazone to imatinib therapy.
- Trial name
- NCT04883125
- Testing
- Pioglitazone 15mg
- Where
- Egypt
- Volunteers
- 90 people
- Sponsor
- Mansoura University
Type 2 Diabetes
Placebo and Active Controlled Study of Rivoglitazone in Type 2 Diabetes
This is a 6-month study to evaluate the effects of monotherapy with rivoglitazone, an insulin sensitizer, on glycemic control in newly identified type 2 diabetics or diabetics not adequately treated with other antidiabetic…
- Trial name
- NCT00143520
- Testing
- Rivoglitazone, Pioglitazone
- Where
- 74 sites in United States
- Volunteers
- 441 people
- Sponsor
- Daiichi Sankyo
Obesity, Metabolic Syndrome
Cellular Dynamics of Subcutaneous Fat Distribution in Obese Women
The body shape of obese women varies between having the majority of fat either above the waist ("apple" shape) or below the waist ("pear" shape).
- Trial name
- Apple/Pear (NCT01748994)
- Testing
- Pioglitazone
- Where
- 2 sites in United States
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- Pennington Biomedical Research Center
Type2 Diabetes, Non-Alcoholic Fatty Liver Disease
Efficacy and Safety of Evoglitin in Patients With Type 2 Diabetes and Non-alcoholic Fatty Liver Diseases
A multicenter, double-blind, active-controlled, randomized, parallel, phase IV clinical trial to evaluate the efficacy and safety of evogliptin in patients with type 2 diabetes and non-alcoholic fatty liver diseases
- Trial name
- NCT03910361
- Testing
- Evogliptin, Pioglitazone
- Where
- 7 sites in South Korea
- Volunteers
- 51 people
- Sponsor
- Dong-A ST Co., Ltd.
Type 2 Diabetes
TriMaster: Study of a DPP4 Inhibitor, SGLT2 Inhibitor and Thiazolidinedione as Third Line Therapy in Patients With Type 2 Diabetes.
The aim of this project is to identify subgroups of patients with type 2 diabetes that respond well or poorly to particular drugs based on particular clinical characteristics such as their weight or kidney function, to enable…
- Trial name
- TriMaster (NCT02653209)
- Testing
- Sitagliptin - DPP4i, Canagliflozin - SGLT2i, Pioglitazone - TZD
- Where
- United Kingdom
- Volunteers
- 525 people
- Sponsor
- Royal Devon and Exeter NHS Foundation Trust
Cancer of the Pancreas
A Phase II Study of Pioglitazone for Patients With Cancer of the Pancreas
This study is being done to determine whether or not addition of the oral medication, pioglitazone to standard chemotherapy, results in improvement of blood tests that measure the body's ability to utilize sugar (glucose and…
- Trial name
- NCT01838317
- Testing
- Pioglitazone
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- University of Texas Southwestern Medical Center
Polycystic Kidney Disease
Use of Low Dose Pioglitazone to Treat Autosomal Dominant Polycystic Kidney Disease
Funding Source - FDA OOPD Pioglitazone is currently used in clinical practice to treat diabetes and this study will examine the potential use of a low dose of the same drug for the treatment of polycystic kidney disease.
- Trial name
- PIOPKD (NCT02697617)
- Testing
- Pioglitazone
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Indiana University
Myositis, Inclusion Body Myositis
Study of Pioglitazone in Sporadic Inclusion Body Myositis
A study looking at the effect of pioglitazone in skeletal muscle of patients with sporadic inclusion body myositis (sIBM).
- Conditions
- Myositis, Inclusion Body Myositis, Muscular Diseases, Musculoskeletal Disease
- Trial name
- NCT03440034
- Testing
- Pioglitazone
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Johns Hopkins University
Diabetes Mellitus, Type 2
Efficacy and Safety of Vildagliptin in Combination With Pioglitazone in Patients With Type 2 Diabetes
Many people with type 2 diabetes cannot maintain target blood glucose levels when taking a single oral drug. The purpose of this study is to assess the safety and effectiveness of vildagliptin, an unapproved drug, in lowering…
- Trial name
- NCT00099853
- Testing
- Vildagliptin, pioglitazone
- Where
- United States
- Volunteers
- 362 people
- Sponsor
- Novartis Pharmaceuticals
Healthy
Drug Interaction Study of MGL-3196 With Pioglitazone
The purpose of this study is to determine whether the single-dose pharmacokinetics (AUC) of pioglitazone are affected by chronic dosing with MGL-3196 100 mg/day in healthy subjects.
- Trial name
- NCT04671056
- Testing
- MGL-3196, Pioglitazone 15mg
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Madrigal Pharmaceuticals, Inc.
Coronavirus Infection, Diabetes
GlitazOne Treatment for Coronavirus HypoxiA, a Safety and Tolerability Open Label With Matching Cohort Pilot Study
Pioglitazone is an approved anti-hyperglycemic medication and is thought to have anti-inflammatory properties. This study seeks to gather safety and tolerability data related to pioglitazone when given to patients who require…
- Trial name
- GOTCHA (NCT04473274)
- Testing
- Pioglitazone
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Samaritan Health Services
Severe Sepsis, Septic Shock
Pharmacokinetic and Biomarker Study of Pioglitazone in Adolescents With Severe Sepsis and Septic Shock
The purpose of this study is to evaluate the pharmacokinetics of pioglitazone and to determine the effect on inflammatory biomarkers for pioglitazone in patients with severe sepsis and septic shock.
- Trial name
- NCT01352182
- Testing
- Pioglitazone hydrochloride
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati